Literature DB >> 23024066

Effect of fever on hospital presentation, diagnosis, and treatment in patients with H1N1/09 influenza.

Madhuri M Sopirala1, Douglas M Haas, Naeem A Ali, Julie E Mangino, Xueliang Pan, Abigail Norris Turner.   

Abstract

OBJECTIVE: Fever is typically considered part of the influenza-like illness in hemagglutinin type 1 and neuraminidase type 1 (H1N1/09) influenza. We assessed the proportion of patients that did not have fever as part of their illness prior to hospital presentation. We assessed the role of fever on the delay in hospital presentation, diagnosis, and treatment of these patients.
METHODS: We performed a retrospective analysis of all hospitalized adult patients with laboratory-confirmed pandemic H1N1/09 at a tertiary care center in the United States from June 1 to December 31, 2009.
RESULTS: Fifty-six of 135 study patients (42%) had no fever; 31 (23%) required intensive care unit (ICU) admission, and 9 (7%) died. Those without fever had higher Charlson index (P = 0.01), significantly longer time to hospital presentation (median 4 vs 2 days, P < 0.001), longer time to treatment since the onset of illness (median 5 vs 2 days, P = 0.001), and were more frequently in an ICU (P = 0.01). After adjustment for age (<40 vs ≥40) and Charlson index (0, 1-2, ≥3), patients without fever had significantly increased likelihood of late hospital presentation (>2 days from the onset of illness) (P = 0.001) and also had increased likelihood of ICU stay (P = 0.05).
CONCLUSIONS: Forty-two percent of patients with laboratory-confirmed H1N1/09 did not have fever as part of their illness prior to hospital presentation. Patients without fever had delayed presentation to the hospital and thus experienced delayed treatment.
Copyright © 2012 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23024066      PMCID: PMC4271823          DOI: 10.1002/jhm.1981

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  14 in total

Review 1.  Neuraminidase inhibitors for influenza.

Authors:  Anne Moscona
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

2.  Likelihood that an unsubtypeable influenza A virus result obtained with the Luminex xTAG respiratory virus panel is indicative of infection with novel A/H1N1 (swine-like) influenza virus.

Authors:  Christine C Ginocchio; Kirsten St George
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

3.  Update: infections with a swine-origin influenza A (H1N1) virus--United States and other countries, April 28, 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-05-01       Impact factor: 17.586

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.

Authors:  Susan K Bowles; Wayne Lee; Andrew E Simor; Mary Vearncombe; Mark Loeb; Susan Tamblyn; Margaret Fearon; Yan Li; Allison McGeer
Journal:  J Am Geriatr Soc       Date:  2002-04       Impact factor: 5.562

6.  Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season.

Authors:  Naoki Kawai; Hideyuki Ikematsu; Norio Iwaki; Ietaka Satoh; Takashi Kawashima; Tetsunari Maeda; Kiyomitsu Miyachi; Nobuo Hirotsu; Takeshi Shigematsu; Seizaburo Kashiwagi
Journal:  Clin Infect Dis       Date:  2005-03-16       Impact factor: 9.079

7.  Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China.

Authors:  Bin Cao; Xing-Wang Li; Yu Mao; Jian Wang; Hong-Zhou Lu; Yu-Sheng Chen; Zong-An Liang; Lirong Liang; Su-Juan Zhang; Bin Zhang; Li Gu; Lian-He Lu; Da-Yan Wang; Chen Wang
Journal:  N Engl J Med       Date:  2009-12-09       Impact factor: 91.245

8.  Early administration of oral oseltamivir increases the benefits of influenza treatment.

Authors:  F Y Aoki; M D Macleod; P Paggiaro; O Carewicz; A El Sawy; C Wat; M Griffiths; E Waalberg; P Ward
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

9.  Clinical and epidemiological profile of patients with severe H1N1/09 pandemic influenza in Australia and New Zealand: an observational cohort study.

Authors:  Allen C Cheng; Tom Kotsimbos; Anna Reynolds; Simon D Bowler; Simon G A Brown; Robert J Hancox; Mark Holmes; Louis Irving; Christine Jenkins; Philip Thompson; Graham Simpson; Grant Waterer; Richard Wood-Baker; Paul M Kelly
Journal:  BMJ Open       Date:  2011-07-20       Impact factor: 2.692

10.  Characteristics of outpatients with pandemic H1N1/09 influenza in a tertiary care university hospital in Korea.

Authors:  Kyung Sun Park; Tae Sung Park; Jin Tae Suh; You Sun Nam; Mi Suk Lee; Hee Joo Lee
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

View more
  1 in total

1.  Influenza With and Without Fever: Clinical Predictors and Impact on Outcomes in Patients Requiring Hospitalization.

Authors:  Benjamin J Smith; David J Price; Douglas Johnson; Bruce Garbutt; Michelle Thompson; Louis B Irving; Mark Putland; Steven Y C Tong
Journal:  Open Forum Infect Dis       Date:  2020-07-03       Impact factor: 3.835

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.